UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040386
Receipt number R000046087
Scientific Title Evaluation of COVID-19 antigen test in COVID-19 suspected cases
Date of disclosure of the study information 2020/07/01
Last modified on 2021/02/15 11:30:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of COVID-19 antigen test in COVID-19 suspected cases

Acronym

Evaluation of COVID-19 antigen test in COVID-19 suspected cases

Scientific Title

Evaluation of COVID-19 antigen test in COVID-19 suspected cases

Scientific Title:Acronym

Evaluation of COVID-19 antigen test in COVID-19 suspected cases

Region

Japan


Condition

Condition

COVID-19

Classification by specialty

Medicine in general Pneumology Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the results of COVID-19 antibody test between the patients who were positive for SARS-CoV-2 and those negative for SARS-CoV-2 in genetic test.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Sensitivity, specificity, PPV, and NPV of COVID-19 antibody test in comparison with genetic test

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1)COVID-19 suspected patient, 2)Patient who was performed genetic test, 3)Patient who was obtained blood sample

Key exclusion criteria

A patient who the attending doctor considered that a patient is not appropriate for the study.

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Katsunori
Middle name
Last name Yanagihara

Organization

Nagasaki University Hospital

Division name

Department of Laboratory Medicine

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki city

TEL

095-819-7574

Email

k-yanagi@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name Norihito
Middle name
Last name Kaku

Organization

Nagasaki University Hospital

Division name

Department of Laboratory Medicine

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki city

TEL

095-819-7574

Homepage URL


Email

kaku-ngs@umin.ac.jp


Sponsor or person

Institute

Nagasaki University

Institute

Department

Personal name



Funding Source

Organization

Nagasaki University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagasaki University Hospital

Address

Sakamoto 1-7-1, Nagasaki City

Tel

095-819-7229

Email

gaibushikin@ml.nagasaki-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 05 Month 13 Day

Date of IRB

2020 Year 05 Month 19 Day

Anticipated trial start date

2020 Year 06 Month 01 Day

Last follow-up date

2023 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

N/A


Management information

Registered date

2020 Year 05 Month 13 Day

Last modified on

2021 Year 02 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046087


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name